Researchers discovered an unexpected link between zinc deficiency, the pro-inflammatory cytokine interleukin-13 (IL-13), and Acinetobacter baumannii lung infection and demonstrated that blocking ...

Nov. 15, 2024 — Researchers discovered an unexpected link between zinc deficiency, the pro-inflammatory cytokine interleukin-13 (IL-13), and Acinetobacter baumannii lung infection and ...

Emboldened by technological advances and a deeper knowledge of glioblastoma, Merck, Kazia Therapeutics, CorriXR Therapeutics ...

The EMA has started a review of Leo Pharma’s interleukin-13 inhibitor tralokinumab as an antibody therapy for atopic dermatitis, a category that is currently dominated by Sanofi and Regeneron ...

A randomized controlled trial found that carrageenan, a common food additive, may cause subclinical inflammation and insulin ...

Bristol-Myers Squibb (BMS) has been steadily building its position in fibrotic diseases for some time, but accelerated its efforts this week with a $1.25 billion deal giving it the right to buy ...

Verona's approval of ensifentrine in COPD offers promising potential with its MoA and safety profile in a competitive market.

15 in the journal Nature Microbiology. A Vanderbilt University Medical Center-led team of researchers discovered an unexpected link between the pro-inflammatory cytokine interleukin-13 (IL-13) and A.

These proteins are called interleukin-4 (IL-4) and interleukin-13 (IL-13). Usually, when IL-4 and IL-13 bind to their receptors, your immune system releases proteins called cytokines. And this ...

The interleukin-4 and interleukin-13 pathways raise fractional exhaled nitric oxide (FeNO) levels and, more generally, enhance eosinophil and type 2 inflammatory cell infiltrations in the lung. In the ...

The therapy simultaneously targets EGFR and interleukin-13 receptor alpha 2. In three clinical studies conducted over the past 10 years, the treatment has produced results that have sparked ...